References
- Allan, D., Koven, A., Wild, A., Kamel-Reid, S. and Dube, I.D. (1996): Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR. Leukem Lymphom., 23, 375-381
- Anttila, S., Hirvonen, A., Vainio, H., Husgafvel-Pursiainen, K., Hayes, J.D. and Ketterer, B. (1993): Immunohistochemical localization of glutathione S-transferases in human lung cancer. Cancer Res., 53, 5643-5648
- Blaese, R.M. (1990): Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency with autologous Iympohocytes transduced with a human ADA gene. Hum. Gene Ther., 1, 327-362
- Blaese, R.M., Culver, K.W., Miller, A.D., Carter, C.S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y, Tolstoshev, P., et al. (1995): T Iympohocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years. Science, 270, 475-480 https://doi.org/10.1126/science.270.5235.475
- Caroline, C., Min, K., Dka, O., Robert, W., Dai, K., Zhuangwu, L., Yung, H.C., Bali, M., Shiv, S., Prem, S. and Kenneth, C. (1998): Effects of adenovirus-mediated p161NK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene, 16, 265-272 https://doi.org/10.1038/sj.onc.1201493
- Costantini, L.C., Bakowska, J.C., Breakefield, X.O. and Isacson, O. (2000): Gene Therapy in the CNS. Gene Therapy, 7, 93-109
- European Society of Gene Therapy 10th Annual Meeting (2002): Adverse event the clinical trial of gene therapy for the X-linked severe combined immune deficiency disease (XSCID)
- Fisher, D.E. ed. (2001): Tumor Suppressor Genes in Human Cancer, Totowa, New Jersey, Humana press, pp.183-195
- Gene Therapy Clinical Trials (2004): J. Gene Med. website (www.wiley.co.uk/genetherapy/clinical/)
-
Gilliland, ED., Harms, H.J., Crowell, R.E., Li, Y.F., Willink, R. and Belinsky, SA (2002): Glutathione S-transferase P1 and NADPH Quinone Oxidoreductase Polymorphisms are associated with aberrant promoter methylation of p161NK4a and
$O^{6}$ -methylguanine-DNA methyltransferase in sputum. Cancer Res., 62, 2248-2252 -
Grimison, B., Langan, T.A. and Sclafani, R.A. (2000):
$P16^{lnk4a}$ tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution. Cell Growth & Differentiation, 11, 507-515 - Habib, NA, Hodgson, H.J.F., Lemoine, N. and Pignatelli, M. (1999): A Phase I/II Study of Hepatic Artery Infusion with wtp53-CMV-AD in Metastatic Malignant Liver Tumours. Human Gene Therapy, 10, 2019-2034 https://doi.org/10.1089/10430349950017383
- Hall, M. and Peters, G. (1996): Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancers. Adv. Cancer Res., 68, 67-108
- Harada, H., Nakagawa, K., Iwata, S. and Saito, M., Kumon, Y, Sakaki, S., Sato, K. and Hamada, K. (1999): Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res., 59, 3783-3789
- Jin, M., Inoue, S., Umemura, T, Moriya, J., Arakawa, M., Nagashima, K. and Kato, H. (2001): Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer, 34, 207-218
- Kamb, A. et al. (1994): A cell cycle regulator potentially involved in genesis of many tumour types. Science, 264, 436-440 https://doi.org/10.1126/science.8153634
- Kataoka, M., Wiehle, S., Spitz, F., Schumacher, G., Roth, JA and Cristiano, R.J. (2000): Down-regulation of bcl-2 is associated with p16lNK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene, 19. 1589-1595
- Kawabe, S., Roth, J.A., Wilson, D.R. and Meyn, R.E. (2000): Adenovirus-mediated p161NK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53dependent manner. Oncogene, 19, 47, 5359-5366
- Kim, M., Katayose, Y, Rojanala, L., Shah, S., Sgagias, M., Jang, L., Jung, YJ., Lee, S.H., Hwang, S.G. and Cowan, K.H. (2000): Induction of apoptosis in p161NK4A mutantcell lines by adenovirus-mediated overexpression of p161NK4A protein. Cell Death and Differentiation, 7, 706-711
- Kobayashi, S., Shirasawa, H., Sashiyama, H., Kawahira, H. and Kaneko, O.T. (1999): p161NK4a expression adenovirus vector to suppress cancer cell proliferation. Clin Cancer Res., 5, 12, 4182-4185
- Lee, J.H., Lee, C.T., Yoo, C.G., Hong, Y.K., Kim, C.M., Han, S.K., Shim, Y.S., Carbone, D.P. and Kim, Y.W. (1998): The inhibitory effect of adenovirus-mediated p161NK4a gene transfer on the proliferation of lung cancer cell line. Anticancer Res., 18, 5A, 3257-3261
- Lee, S.H., Kim, M.S., Kwon, H.C., Park, I.C., Park, M.J., Lee, C.T, Kim, Y.W., Kim, C.M. and Hong, S.I. (2000): Growth inhibitory effect on glioma cells of adenovirus-mediated p16/1NK4a gene transfer in vitro and in vivo. Int J. Mol. Med., 6, 559-563
- Mannervik, B. and Danielson, U.H. (1988): Glutathione transferases - structure and catalytic activity. CRC Crit. Rev. Biochem., 23, 283-337
- Melcher, A., Murphy, S. and Vile, R. (1999): Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Human Gene Therapy, 10, 1431-1442 https://doi.org/10.1089/10430349950017770
- Niklinski, J., Niklinska, W, Laudanski, J., Chyczewska, E. and Chyczewski, L. (2001): Prognostic molecular markers in non-small cell lung cancer. Lung Cancer, 34, S53-S58
- Park, K.H., Seol, J.Y, Kim, T.U., Yoo, C.G., Kim, Y.W, Han, S.K., Shim, Y.S. and Lee, C.T. (2001): An Adenovirus Expressing Mutant p27 Showed More Potent Antitumor Effects Than Adenovirus-p27 Wild Type. Cancer Res., 61, 6163-6169
- Pilaro, A.M. and Serabian, M.A. (1999): Safety Evaluation of Gene Therapies : Past, Present and Future. ASGT 2nd meeting
- Ranade, K. et al. (1995) : Mutations associated with familial melanoma impair p161NK4 function. Nature Genet., 10, 114-116
- Raymon, H.K., Thode, S. and Gage, F.H. (1997): Application of ex Vivo Gene Therapy in the Treatment of Parkinson's Disease. Experimental Neurology, 144, 82-91 https://doi.org/10.1006/exnr.1996.6392
- Roth, J.A., Swisher, S.G., Merritt, J.A., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., EI-Naggar, A.K., Fossella, F.V., Glisson, B.S., Hong, W.K., Khurl, F.R., Kurie, J.M., Nesbitt, J.C., Pisters, K., Putnam, J.B., Schrump, D.S., Shin, D.M., Walsh, G.L. (1998): Gene therapy for nonsmall cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol, 25(3 SuppI8), 33-37
- Seroogy, C.M. and Fathman, C.G. (2000): The application of gene therapy in autoimmune diseases. Gene Therapy, 7, 9-13
- Smith, K.T., Shepherd, A.J., Boyd, J.E. and Lees, G.M. (1996): Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Gene Therapy, 3, 190-200
- the European Agency for the Evaluation of Medicinal Products (2001): Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products
- U.S. NIH report (2002): Assessment of adenoviral vector safety and toxicity : report of the national institutes of health recombinant DNA advirosry committee. Human Gene Therapy, 13, 3-13
- US FDA Center for Biologics Evaluation and Research, biological Response Modifiers Advisory Committee Meeting #33 (2002)
- US FDA Center for Biologics Evaluation and Research, Guidance for industry (1998): Guidance for Human Somatic Cell Therapy and Gene Therapy.
- Vile, R.G., Russell, S.J., and Lemoine, N.R. (2000): Cancer gene therapy: hard lessons and new courses. Gene Therapy, 7, 2-8
- Vogt, P., Reed, S. In: Vogt, P., Reed, S. eds. (1998): Cyclin Dependent Kinase (CDK) Inhibitors, Berlin, Heidelberg: Springer-Verlag, 139-148
- Winn, R.A., Bremnes, R.M., Bemis, L., Franklin, W.A., Miller, Y.E., Cool, C. and Heasley, L.E. (2002): Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 21, 7497-7506
- Wu, Q., Moyana, T. and Xiang, J. (2001): Cancer gene therapy by adenovirus-mediated gene transfer. Curr. Gene Ther., 1, 101-122
- Zhang, L.Y., Ying, W.T., Mao, Y.S., He, H.Z., Liu, Y.L., Wang, H.X., Liu, F., Wang, K., Zhang, D.C., Wang, Y, Wu, M., Qian, X.H. and Zhao, X.H. (2003): Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J. Gastroenterol., 9, 650-654
- Verdier, F. and Descotes, J. (1999): Preclinical safety evaluation of human gene therapy products. Toxicological Sciences, 47, 9-15